臺灣博碩士論文加值系統

糖尿病腎病變是由於體內長期處於高血糖狀態而誘發氧化壓力及發炎所造成之小血管併發症。研究指出，桑黃(Phellinus linteus)具有抗腫瘤、抗氧化、抗發炎及降血糖等功效，但是否具有改善腎功能之作用則尚未明瞭。故本研究目的為探討桑黃菌絲體對改善糖尿病大鼠腎病變之影響。實驗以STZ (50 mg/kg BW/i.p.)誘發糖尿病大鼠之模式，將60隻四週齡的Wistar大鼠，分為健康對照組、糖尿病對照組、桑黃低劑量組(100 mg/kg/BW)、桑黃中劑量組(200 mg/kg/BW)及桑黃高劑量組(500 mg/kg/BW)。桑黃菌絲體以管餵方式給予，實驗為期12週，在實驗前、後測其空腹血糖值，並於犧牲前收集24小時尿液，犧牲後收集血液及腎臟樣本並分析血糖代謝指標(禁食血糖及脂聯素)、腎功能指標(BUN、serum creatinine、urine creatinine、Ccr、UAE及ACR)、抗氧化指標(ROS、AGE、GSH)及發炎反應指標(TNF-α)。結果顯示，桑黃菌絲體之補充，可有效降低糖尿病鼠空腹血糖值並提升血漿脂聯素濃度。桑黃菌絲體之補充可提升糖尿病鼠腎臟組織GSH之含量，並抑制ROS與AGEs之生成。中、高劑量桑黃菌絲體之補充也可顯著降低促發炎細胞激素TNF-α之濃度。中劑量桑黃菌絲體之補充更能有效改善腎功能指標Ccr、UAE及ACR。綜合上述得知，中劑量桑黃菌絲體之補充，能藉由改善糖尿病大鼠之空腹血糖值，提升腎臟組織抗氧化能力，抑制糖化終產物及發炎物質之生成，進而保護腎臟組織並提升腎功能，達到延緩糖尿病腎病變之功效。

Diabetic nephropathy is one of the microvascular complications, which is caused by long-term hyperglycemia-induced oxidative stress and inflammation. Previous studies have indicated that Phellinus linteus has anti-tumor, anti-oxidation, anti-inflammatory and hypoglycemic effects, however, it is unclear its effect on renal function. Therefore, the purpose of this study was to investigate the effect of P. linteus on nephropathy in diabetic rats. Sixty male Wistar rats were randomly assigned into five groups: Normal controls group (NC group), Diabetic control group (DC group), diabetic rats fed with low dose group (100 mg/kg BW) (LD group), medium dose group (200 mg/kg BW) (MD group) and high dose group (500 mg/kg BW) of P. linteus mycelium powder (HD group). Normal control and diabetic rats were gavaged with saline and P. linteus mycelium powder respectively for 12 week then sacrificed. Concentration of fasting glucose, adiponectin, renal function (BUN, Scr, Ucr, Ccr, UAE and ACR), anti-oxidative markers (ROS, AGEs and GSH) and pro-inflammatory markers (TNF-α) were measured. The results of this study showed that supplementation of P. linteus mycelium decreased fasting blood glucose and increased plasma adiponectin concentration. P. linteus supplementation also increased GSH content and inhibited the production of ROS and AGEs in the kidney of diabetic rats. TNF-α concentration decreased significantly in MD and HD groups. Ccr, UAE and ACR also improved in MD group. In conclusion, these results suggest that 200 mg/kg BW of P. linteus mycelium powder could attenuate diabetes associated oxidative and inflammatory stress in kidneys of diabetic rats.

目錄 I
表目錄 II
圖目錄 III
中文摘要 IV
英文摘要 V
第一章、前言 1
第二章、文獻回顧 2
第一節、糖尿病之簡介 2
第二節、糖尿病腎病變 6
第三節、桑黃 13
第四節、研究目的 16
第三章、材料與方法 17
第一節、實驗材料 17
第二節、動物實驗與設計 19
第三節、實驗分析方法 20
第四節、統計分析 28
第四章、結果 29
第一節、桑黃菌絲體對STZ誘發糖尿病大鼠攝食量、飲水量及體重之影響 29
第二節、桑黃菌絲體對STZ誘發糖尿病大鼠血糖代謝之影響 29
第三節、桑黃菌絲體對STZ誘發糖尿病大鼠腎功能之影響 30
第四節、桑黃菌絲體對STZ誘發糖尿病大鼠抗氧化之影響 31
第五節、桑黃菌絲體對STZ誘發糖尿病大鼠發炎之影響 32
第五章、討論 42
第一節、桑黃菌絲體對STZ誘發之糖尿病大鼠血糖代謝之探討 42
第二節、桑黃菌絲體對STZ誘發之糖尿病大鼠腎功能之探討 44
第三節、桑黃菌絲體對STZ誘發之糖尿病大鼠氧化與發炎之探討 46
第六章、結論 49
第七章、參考文獻 50

王薇猗(2006)。桑黃生物活性之研究與應用。食品工業，38，25-34。
台灣腎臟醫學會(2006)。台灣腎臟醫學會透析年度報告。台北市：台灣腎臟醫學會。
行政院衛生福利部(2016)。統計處。2016.09.08取自http://www.mohw.gov.tw/CHT/DOS/DisplayStatisticFile.aspx?d=56398
李佩賢、張弘育、董淳武、徐永建、雷振宙、張洵浩、施雅雪、林俊良(2009)。一個容易被忽略的徵兆：微白蛋白尿。內科學誌，20，275-84。
林泠、王兆民、楊博凱、陳寶珍、蔡明怡、黃雅芳(譯)(2008)。人體生理學(原作者：L. Sherwood )。台北市：湯姆生。(原著出版年：2007)。
孫淑靜、江玉姬、朱虎、謝寶貴(2005)。藥用真菌桑黃的研究現狀。藥物生物技術，12，138-40。
高木繁(2004)。桑黃。台北市：青春出版社。
張萬國、胡晉紅(2002)。桑黃預防大鼠肝纖維化作用的實驗研究。藥學服務與研究，2，82-6。
張萬國、胡晉紅、蔡溱(2002)。桑黃增強人外周血單個核細胞產生γ-干擾素的研究。基層中藥雜誌，16，5-6。
張嘉仁(2010)。糖尿病視網膜病變。台灣醫界，53，282-6。
莊書碩(2003)。糖尿病的進展與治療評估。基層醫學，18，188-91。
溫克、陳勁、李紅、黛文丸、李敬軒、楊世杰(2002)。桑黃等四種抗癌藥物抗癌活性比較。吉林大學學報（醫學版），28，247-249。
American diabetes association. Peripheral arterial disease in people with diabetes. Diabetes Care. 2003;26:3333-41.
American Diabetes Association. Standards of Medical Care in Diabetes-2016. Diabetes Care. 2016;39:S13-S22.
Aronson D. Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol. 2008;45:1-16.
Arora MK, Singh UK. Oxidative stress: meeting multiple targets in pathogenesis of diabetic nephropathy. Curr Drug Targets. 2014;15:531-8.
Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, Standl E,Soler-Soler J, Ohrvik J. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J. 2004;25:1880-90.
Bassi AM, Ledda S, Valentini S, De Pascale MC, Rossi S, Odetti P, Cottalasso D. Damaging effects of advanced glycation end-products in the murine macrophage cell line J774A.1.Toxicol In Vitro. 2002;16:339-47.
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and anagement. JAMA. 2002;287:2570-81.
Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001;7:947-53.
Boulton AJ. Lowering the risk of neuropathy, foot ulcers and amputations. Diabet Med. 1998;15:57-9.
Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes. 2000;49:1399-408.
Cavanagh ES, MacLeod L, Kennedy CRJ. The Podocyte in Diabetic Kidney Disease. ScientificWorldJournal. 2009;9:1127-39.
Cerriello A, Quatraro A, Giugliano D. Diabetes mellitus and hypertension: the possible role of hyperglycemia through oxidative stress. Diabetologia. 1993;36:265-6.
Chang HY, Sheu MJ, Yang CH, Lu TC, Chang YS, Peng WH, Huang SS, Huang GJ. Analgesic effects and the mechanisms of anti-inflammation of hispolon in mice. Evid Based Complement Alternat Med. 2011;2011:1-8. 
Chow FY, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol Dial Transplant. 2004;19:2987-96.
Dabla PK. Renal function in diabetic nephropathy. World J Diabetes. 2010;1:48-56.
Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab.2008;4,444-52.
Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, Wilson DM, O'Brien PC, Melton LJ 3rd, Service FJ. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817-24.
Elissa LA, Elsherbiny NM, Magmomah AO. Propolis restored adiponectin level in type 2 diabetes through PPARγ activation. EJBAS. 2015;2:318-26.
Fatehi-Hassanabad Z, Chan CB, Furman BL. Reactive oxygen species and endothelial function in diabetes. Eur J Pharmacol. 2010;636:8-17.
Feskens EJ, Kromhout D. Glucose tolerance and the risk of cardiovascular disease: the Zutphen Study. J Clin Epidemiol. 1992;45:1327-34.
Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes. 2008;57:1446-54.
Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 2003;17:1762-4.
Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A. 2001;98:2005-10.
Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058-70. 
Gray CS, Scott JF, French JM, Alberti KGMM, O’Connell JE. Prevalence and prediction of unrecognized diabetes mellitus and impaired glucose tolerance following acute stroke. Age Ageing. 2004;33:71-7.
Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR. Diabetes and cardiovascular disease a statement for healthcare professionals from the American heart association. Circulation. 1999;100:1134-46.
Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int. 2001;60,14-30.
Ha Y, Saul A, Tawfik A, Zorrilla EP, Ganapathy V, Smith SB. Diabetes accelerates retinal ganglion cell dysfunction in mice lacking sigma receptor 1. Mol Vis. 2012;18:2860-70.
Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34.
Han SB, Lee CW, Kang JS, Yoon YD, Lee KH, Lee K, Park SK, Kim HM. Acidic polysaccharide from Phellinus linteus inhibits melanoma cell metastasis by blocking cell adhesion and invasion. Int Immunopharmacol. 2006;6:697-702.
Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, van Ypersole de Strihou C, Monnier VM, Witztum JL, Kurokawa K. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest. 1997;100:2995-3004.
Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996;271:10697-703.
HUI Jing, LI Hui, ZHU Chun-yu, LI Qi-jiu,HU Feng-qing. Comparative Analysis of Nutrients in Fruit Body and Mycelia of Phellinus igniarius. Special Wild Economic Animal and Plant Research. 2009;2:59-61.
Hur JM, Yang CH, Han SH, Lee SH, You YO, Park JC, Kim KJ. Antibacterial effect of Phellinus linteus against methicillin-resistant Staphylococcus aureus. Fitoterapia. 2004;75:603-5.
Hwang HJ, Kim SW, Lim JM, Joo JH, Kim HO, Kim HM, Yun JW. Hypoglycemic effect of crude exopolysaccharides produced by a medicinal mushroom Phellinus baumii in streptozotocin-induced diabetic rats. Life Sci. 2005;76:3069-80.
International Diabetes Federation. IDF Diabetes atlas, Seventh edition, 2015. Retrieved from http://www.diabetesatlas.org/
Jang JS, Lee JS, Lee JH, Kwon DS, Lee KE, Lee SY, Hong EK. Hispidin produced from Phellinus linteus protects pancreatic beta-cells from damage by hydrogen peroxide. Arch Pharm Res. 2010;33:853-61.
Jansson PA. Endothelial dysfunction in insulin resistance and type 2 diabetes. J Intern Med. 2007;262:173-83.
Jeganathan VS, Wang JJ, Wong TY. Ocular associations of diabetes other than diabetic retinopathy. Diabetes Care. 2008;31:1905-12.
Jung JY, Lee IK, Seok SJ, Lee HJ, Kim YH, Yun BS. Antioxidant polyphenols from the mycelial culture of the medicinal fungi Inonotus xeranticus and Phellinus linteus. J Appl Microbiol. 2008;104:1824-32.
Kashihara N, Haruna Y, Kondeti VK, Kanwar YS. Oxidative Stress in Diabetic Nephropathy. Curr Med Chem. 2010;17:4256-69.
Kempen JH, O’Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, Taylor HR, Hamman RF. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122:552-63.
Khansari N, Shakiba Y, Mahmoudi M. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat Inflamm Allergy Drug Discov. 2009;3:73-80.
Kiho T, Kochi M, Usui S, Hirano K, Aizawa K, Inakuma T. Antidiabetic effect of an acidic polysaccharide (TAP) from Tremella aurantia and its degradation product (TAP-H). Biol Pharm Bull. 2001;24:1400-3. 
Kim DH, Yang BK, Hur NJ, Das S, Yun JW, Choi YS, Song CH. Hypoglycemic effects of mycelia produced from a submerged culture of Phellinus linteus (Berk. et Curt.) Teng (Aphyllophoromycetideae) in streptozotocin-lnduced diabetic rats. Int J Med Mushr. 2001a;3:21-6.
Kim DH, Yang BK, Jeong SC, Park JB, Cho SP, Das S, Yun JW, Song CH. Production of a hypoglycemic, extracellular polysaccharide from the submerged culture of the mushroom, Phellinus linteus. Biotechnol Lett. 2001b;23:513-7.
Kim GY, Roh SI, Park SK, Ahn SC, Oh YH, Lee JD, Park YM. Alleviation of experimental septic shock in mice by acidic polysaccharide isolated from the medicinal mushroom Phellinus linteus. Biol Pharm Bull. 2003;26:1418-23.
Kim HM, Han SB, Oh GT, Kim YH, Hong DH, Hong ND, Yoo ID. Stimulation of humoral and cell mediated immunity by polysaccharide from mushroom Phellinus linteus. Int J immunopharmacol. 1996;18:295-303.
Kim HM, Kang JS, Kim JY, Park SK, Kim HS, Lee YJ, Yun J, Hong JT, Kim Y, Han SB. Evaluation of antidiabetic activity of polysaccharide isolated from Phellinus linteus in non-obese diabetic mouse. Int Immunopharmacol. 2010;10:72-8.
Kim SH, Lee HS, Lee S, Cho J, Ze K, Sung J, Kim YC. Mycelial culture of Phellinus linteus protects primary cultured rat hepatocytes against hepatotoxins. J Ethnopharmacol. 2004b;95:367-72.
Kim SH, Song YS, Kim SK, Kim BC, Lim CJ, Park EH. Anti-inflammatory and related pharmacological activities of the n-BuOH subfraction of mushroom Phellinus linteus. J Ethnopharmacol. 2004a;93:141-6.
Kintscher U, Law RE. PPARgamma-mediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab. 2005;288,E287-91.
Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, Schleicher ED. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest. 1998;101:160-9. 
Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47:859-66.
Kuhad A, Chopra K. Attenuation of diabetic nephropathy by tocotrienol: Involvement of NFκB signaling pathway. Life Sci. 2009;84:296-301.
Lee HT, Kim M, Jan M, Emala CW. Anti-inflammatory and antinecrotic effects of the volatile anesthetic sevoflurane in kidney proximal tubule cells. Am J Physiol Renal Physiol. 2006a;291,F67-78.
Lee JH, Lee JS, Kim YR, Jung WC, Lee KE, Lee SY, Hong EK. Hispidin isolated from Phellinus linteus protects against hydrogen peroxide-induced oxidative stress in pancreatic MIN6N β-cells. J Med Food. 2011;14:1431-8.
Lee JH, Lee SJ, Choi YH, Chung KT, Jeong YK, Choi BT. Effects of mycelial culture of Phellinus linteus on ethanol-induced gastric ulcer in rats. Phytother Res. 2006b;20:396-402.
Lee YS, Kang YH, Jung JY, Lee S, Ohuchi K, Shin KH, Kang IJ, Park JH, Shin HK, Lim SS. Protein glycation inhibitors from the fruiting body of Phellinus linteus. Biol. Pharm. Bull. 2008;31:1968-72.
Li G, Kim DH, Kim TD, Park BJ, Park HD, Park JI, Na MK, Kim HC, Hong ND, Lim K, Hwang BD, Yoon WH. Protein-bound polysaccharide from Phellinus linteus induces G2/M phase arrest and apoptosis in SW480 human colon cancer cells. Cancer Lett. 2004;216:175-81.
MaCarthy E, Sharma R, Sharma M, Li JZ, Ge XL, Dileepan KN, Savin VJ: TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol. 1998;9:433-8.
Mauer SM, Steffes MW, Azar S, Brown DM. Effects of sorbinil on glomerular structure and function in long-term-diabetic rats. Diabetes. 1989;38:839-46.
Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int. 2007;72,1367-73.
Mogensen CE, Damsgaard EM, Frøland A, Nielsen S, de Fine Olivarius N, Schmitz A. Microalbuminuria in non-insulin-dependent diabetes. Clin Nephrol. 1992;38:S28-39.
Morgan CLl, Currie CJ, Stott NCH, Smithers M, Butler CC, Peters JR.The prevalence of multiple diabetes-related complications. Diabet Med. 2000;17:146-51.
Morrison J, Knoll K, Hessner MJ, Liang M. Effect of high glucose on gene expression in mesangial cells: upregulation of the thiol pathway is an adaptational response. Physiol Genomics. 2004;17:271-82.
Narita I, Alchi B, Omori K, Sato F, Ajiro J, Saga D, Kondo D, Skatsume M, Maruyama S, Kazama JJ, Akazawa K, Gejyo F, Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int. 2006;69,1626-32.
Navarro-González JF and Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. Clin J Am Soc Nephrol. 2008;19:433-42.
Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, García-Pérez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7:327-40.
Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP. Serum cystatin C: a replacement for creatinine as a biochemical marker of GFR. Kidney Int Suppl. 1994;47,S20-21.
Palsamy P, Subramanian S. Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim Biophys Acta. 2011;1812:719-31.
Park IH, Chung SK, Lee KB, Yoo YC, Kim SK, Kim GS, Song KS. An antioxidant hispidin from the mycelial cultures of Phellinus linteus. Arch Pharm Res. 2004;27:615-8.
Putt DA, ZhongQ, Lash LH. Adaptive changes in renal mitochondrial redox status in diabetic nephropathy. Toxicol Appl Pharmacol. 2012;258:188-98. 
Reddy GR, Kotlyarevska K, Ransom RF, Menon RK. The podocyte and diabetes mellitus: is the podocyte the key to the origins of diabetic nephropathy? Curr Opin Nephrol Hypertens. 2008;17,32-6.
Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest. 2014;124:2333-40.
Saaddine JB, Honeycutt AA, Narayan KM, Zhang X, Klein R, Boyle JP. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005–2050. Arch Ophthalmol. 2008;126:1740-7.
Sailaja YR, Baskar R, Saralakumari D. The antioxidant status during maturation of reticulocytes to erythrocytes in type 2 diabetics. Free Radic Biol Med. 2003;35:133-9.
Sartoretto JL, Oliveira MA, Nigro D, Carvalho MH, Tostes RC, Fortes ZB. Constrictor responses to noradrenaline, hemodynamic profile, and superoxide levels measured by hydroethidine oxidation in diabetic rats. Biol Pharm Bull. 2007;30:1938-42.
Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci. 2005;109:143-59.
Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol. 2005;16:S30-3.
Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270:26746-9.
Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 2002;288:2579-88.
Shon YH, Nam KS. Antimutagenicity and induction of anticarcinogenic phase II enzymes by basidiomycetes. J Ethnopharmacol. 2001;77:103-9.
Song YS, Kim SH, Sa JH, Jin C, Lim CJ, Park EH. Anti-angiogenic, antioxidant and xanthine oxidase inhibition activities of the mushroom Phellinus linteus. J Ethnopharmacol. 2003;88:113-6.
Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J Med Res. 2007;125:451-72.
Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest. 2011;121:2094-101.
Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol. 2000;279:1005-28.
Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823-8.
United States Renal Data System. US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2016;67: S1-305.
Van den Oever IA, Raterman HG, Nurmohamed MT, Simsek S. Endothelialdysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators Inflamm.2010;2010:792393.
Vidotti DB, Casarini DE, Cristovam PC, Leite CA, Schor N, Boim MA. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol. 2004;286, F1039-45.
Wang HY, Bao JL. Effect of houttuynia cordata aetherolea on adiponectin and connective tissue growth factor in a rat model of diabetes mellitus. J Tradit Chin Med. 2012;32:58-62.
Wang S, Mitu GM, Hirschberg R. Osmotic polyuria: An overlooked mechanism in diabetic nephropathy. Nephrol Dial Transplant. 2008;23:2167-72.
Wang SJ, Wang YF, Zheng RZ, Zhao ZG and Ma YH. Osteoinductive factor is a novel biomarker for the diagnosis of early diabetic nephropathy. Int J Clin Exp Pathol. 2015;8:3110-5.
Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol. 2007;106,26-31.
Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int.1999;56,393-405.
Wu CH, Huang CM, Lin CH, Ho YS, Chen CM, Lee HM. Advanced glycation end-products induce NF-kappaB dependent iNOS expression in RAW 264.7 cells. Mol Cell Endocrinol. 2002;194:9-17.
Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets. 2007;8:952-9.
Yang Hua, Zeng Juanhua. Clinical Study on the Relationship between Serum TNF and Type 2 Diabetic Nephropathy. Western Journal of Traditional Chinese Medicine. 2014;27:11-3.
Yaqoob M, McClelland P, Patrick AW, Stevenson A, Mason H, White MC, Bell GM. Evidence of oxidant injury and tubular damage in early diabetic nephropathy. QJM. 1994;87:601-7.
Yeo TK, Senger DR, Dvorak HF, Freter L, Yeo KT. Glycosylation is essential for efficient secretion but not for permeability-enhancing activity of vascular permeability factor (vascular endothelial growth factor). Biochem Biophys Res Commun. 1991;179:1568-75.
Yoshida SI, Hashimoto T, Kihara M, Imai N, Nomura K, Hirawa N, Toya Y, Kitamura H, Umemura S. Urinary oxidative stress markers closely reflect the efficacy of Candesartan treatment for diabetic nephropathy. Nephron Exp Nephrol. 2008;111:20-30.
Yuan C, Huang X, Cheng L, Bu Y, Liu G, Yi F, Yang Z, Song F.Evaluation of antioxidant and immune activity of Phellinus ribis glucan in mice. Food Chem. 2009;115:581-4.
Zhao C, Liao Z, Wu X, Liu Y, Liu X, Lin Z, Huang Y, Liu B. Isolation, purification, and structural features of a polysaccharide from Phellinus linteus and its hypoglycemic effect in alloxan-induced diabetic mice. J Food Sci. 2014;79:1002-10.
Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev. 2008;4:39-45.